The Departments of Anesthesiology and Neurology hosts: “Perivascular Spaces in the Brain & Contributions to Pathology of Cerebral Small Vessel Disease”
Perivascular space and cerebral small vessel disease mini-symposium March 24th in the Brady Memorial Auditorium 1:30-4:30pm
The panel will feature the following Speakers:
- Joanna M. Wardlaw (Professor of Applied Neuroimaging and Director of Edinburgh Imaging, University of Edinburgh) “Perivascular Spaces in the Brain: Anatomy, Physiology, and Contributions to Pathology of Small Vessel Disease”
- (Professor of Neurology and Neuroscience): “Optical Interrogation of Neurovascular and Myelin Pathophysiology in the Live Mammalian Brain”
- (Professor of Anesthesiology): “Delayed cerebral ischemia in SAH - mechanisms and opportunities for intervention”
- (Professor of Stroke Medicine, University of Nottingham): “Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventions”
Speakers:
| Joanna Wardlaw, MD FRCR FRCP FMedSci FRSE CBE Professor of Applied Neuroimaging and Director of Edinburgh Imaging University of Edinburgh, UK | Jaime Grutzendler, MD Professor of Neurology and Neuroscience Director, Center for Experimental Neuroimaging Yale School of Medicine, New Haven |
| Miriam Treggiari, MD, PhD, MPH Professor of Anesthesiology, Vice Chair of Clinical Research, Yale School of Medicine, New Haven | Phillip Bath, M.D., F.R.C.P., FMedSci Professor of Stroke Medicine University of Nottingham, UK |
Contacts: Jennifer Vissagio Jennifer.vissagio@yale.edu 203 785 3358
Host Organizations: Anesthesiology and Neurology
Precis: Cerebral small vessel disease (cSVD) are a group of disorders that result from pathological alteration of the small blood vessels in the brain and rank as the most common pathology in vascular dementia. Of the nearly 35-36 million people that are estimated to suffer from dementia worldwide, up to 65% have an cSVD component. Unfortunately, the prevalence of SVD is increasing and effective disease-modifying interventions are yet to be found. In recent years, there has been tremendous growth in new diagnostic information, a greater understanding of cSVD risk factors as well as instigation of new large clinical trials of repurposed drugs in cSVD to prevent dementia and stroke.
Moderator: Helene Benveniste, MD, PhD